Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France

Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a
pharmaceutical company focusing on the development and
commercialisation of hospital and orphan products, and Primex
Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical
company, announced a strategic agreement today to launch OZALIN® in
France.

One of the challenges facing paediatric anaesthetists in treating
children, either for premedication prior to surgery or during
procedural sedation, is the lack of acceptable approved medications.
An innovative oral solution for children older than 6 months,
OZALIN®, has been approved in several markets in the EU including
France, to improve the palatability and acceptability for children.

"The partnership with Nordic Group represents an important
achievement for Primex Pharmaceuticals and underscores our commitment
to making OZALIN® available across all EU member states," said Alan
Knox, Primex's Group CEO. "We are confident that Nordic Group with
their experience in the hospital sector, will further support their
portfolio in Anaesthesia in France."

Vincent Leonhardt, Managing Director of Nordic Pharma in France
said: "Nordic Pharma is delighted to have the opportunity to
commercialize OZALIN®, a product initially developed at Amiens
hospital in France, and that will make a fundamental difference to
children and their acceptability toward treatment."

About Primex Pharmaceuticals:

Primex Pharmaceuticals is a leading global innovative anaesthesia
company, expanding in paediatric pharmaceuticals. Primex brings a
broad portfolio of anaesthesia products helping patients undergo a
wide range of medical procedures, including a novel, oral solution
for paediatric sedation now approved in several markets in the
European Union. Primex Pharmaceuticals is headquartered in
Switzerland.

www.primexpharma.com

About Nordic Group:

Nordic Group is a privately-owned pan-European pharmaceutical
company with a presence in 17 countries. It focuses on the
development and commercialisation of hospital and orphan products to
respond to unmet medical needs. Nordic Group expertise relies on the
development and sales of its own products, but also on partner
products acquired at various stages of development.

https://www.nordicpharma.fr/

© Primex Pharmaceuticals AG, Zug, Switzerland. All rights reserved

For further information,
please contact:
Primex Pharmaceuticals Nordic Pharma SAS
AG
Alan Knox, CEO Vincent Leonhardt, Managing
Director
Zug, Switzerland Paris, France
Tel. +41-(0)79-1762420 Tel. +33-(0)1-70-37-63-82
alan.knox@primexintl.com vincent.leonhardt@nordicpharma.com

ots Originaltext: Primex Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Primex Pharmaceuticals, übermittelt durch news aktuell